Berkowitz, Elchonon M.
https://orcid.org/0000-0003-2953-894X
Mayo Clinic
GlaxoSmithKline (United States)
Citations 1
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
Stadtmauer, Edward A. , Marty, Francisco M. , Dadwal, Sanjeet , Papanicolaou, Genovefa A. , Shea, Thomas C., Mossad, Sherif B. , Young, Jo‐Anne H. , Idrissi, Mohamed El , Heineman, Thomas C. , Berkowitz, Elchonon M. , Buadi, Francis K. , Sullivan, Keith M. , Andreadis, Charalambos Babis , Young, Jo-Anne H
Blood | September 19, 2014 | Volume: 124 | Issue: 19 | Pages: 2921-2929
Key PointsHCT recipients have increased susceptibility to herpes zoster, but live-attenuated vaccines are not appropriate for highly immunocompromised people. An adjuvanted subunit vaccine against herpes zoster elicits strong immune responses with an acceptable safety profile in adult autologous HCT recipients.